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Objective: The construction of an autogenous radial-cephalic direct wrist arteriovenous fistula (RCAVF) is the primary
and best option for vascular access for hemodialysis. However, 10%-24% of RCAVFs thrombose directly after operation
or do not function adequately due to failure of maturation. In case of poor arterial and/or poor venous vessels for
anastomosis, the outcome of RCAVFs may be worse and an alternative vascular access is probably indicated. A prosthetic
graft implant may be a second best option. Therefore, a randomizedmulticenter study comparing RCAVFwith prosthetic
(polytetrafluoroethylene [PTFE]) graft implantation in patients with poor vessels was performed.
Methods: A total of 383 consecutive new patients needing primary vascular access were screened for enrollment in a
prospective randomized study. According to defined vessel criteria from the preoperative duplex scanning, 140 patients
were allocated to primary placement of an RCAVF and 61 patients to primary prosthetic graft implantation. The
remaining 182 patients were randomized to receive either an RCAVF (n  92) or prosthetic graft implant (n  90).
Patency rate was defined as the percentage of AVFs that functioned well after implantation.
Results: Primary and assisted primary 1-year patencies were 33% 5.3% vs 44% 6.2% (P .03) and 48% 5.5% vs 63%
 5.9% (P .035) for the RCAVF and prosthetic AVF, respectively. Secondary patencies were 52% 5.5% vs 79% 5.1%
(P  .0001) for the RCAVF and prosthetic AVF, respectively. Patients with RCAVFs developed a total of 102
(1.19/patient-year [py]) vs 122 (1.45/py; P  .739) complications in the prosthetic AVFs. A total of 43 (0.50/py)
interventions in the RCAVF group and 79 (0.94/py) in the prosthetic graft group were needed for access salvage (P 
.077).
Conclusions: Although there were more interventions needed for access salvage in the patients with prosthetic graft
implants, we may conclude that patients with poor forearm vessels do benefit from implantation of a prosthetic graft for
vascular access. ( J Vasc Surg 2005;42:481-7.)A well-functioning vascular access remains the lifeline
of end-stage renal disease patients needing chronic inter-
mittent hemodialysis. The Kidney Dialysis Outcomes
Quality Initiative (K/DOQI) and European guidelines for
vascular access propose the construction of an autogenous
radial-cephalic direct wrist arteriovenous fistula (RCAVF)
as the primary and best option.1,2 The usefulness of an
RCAVF depends on an efficient dilatation and arterializa-
tion of the forearm veins used for the creation of arterio-
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doi:10.1016/j.jvs.2005.05.025venous anastomosis, which makes repeated successful can-
nulations possible. RCAVFs that mature without any early
complicationsmay function formany years. However, 10%-
24% of RCAVFs thrombose directly after operation or do
not function adequately due to failure of maturation.3-7
This results in delay of initiation of dialysis treatment with
the need for placement of central venous catheters with
their related morbidity and mortality. Usually, arterio-
venous fistula (AVF) nonmaturation depends on the qual-
ity and size of the vessels used for the arteriovenous anas-
tomosis and the ability of vessel adaptation induced by the
augmented blood flow volumes. To predict successful
maturation, duplex-derived criteria have shown beneficial
effects of using well-sized radial arteries and cephalic
veins.8-10
In cases of very small or diseased arteries and/or veins,
the risk of access failure is probably higher and an alterna-
tive vascular access may be considered. However, there are
only few data on the outcome of RCAVFs in patients with
poor or questionable vessels, and no information on the
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able. An upper arm direct AVF, anastomosing the brachial
artery with the cephalic or basilic vein may be a good
second best option after failure of an RCAVF, but in
K/DOQI guidelines, no consensus for either this option or
the implantation of a prosthetic graft implant has been
outlined. In addition, upper arm access has a considerably
higher incidence of peripheral ischemia and cardiac failure
due to high access flow. Therefore, to address this subject,
we performed a randomized multicenter study comparing
RCAVF vs forearm prosthetic graft (polytetrafluoroethyl-
ene [PTFE]) implantation in patients with poor (question-
able) vessels.
METHODS
Between January 1999 and April 2003, 383 consecu-
tive new patients from six dialysis facilities with end-stage
renal failure were screened for enrollment in the study. This
study was approved by the Medical Ethics Committee of all
participating hospitals. According to the defined vessel
criteria from the preoperative duplex scanning, 140 pa-
tients were allocated to primary placement of an RCAVF
and 61 patients to primary prosthetic graft implantation.
The remaining 182 patients (97 men, 85 women; mean
age, 59 years) were randomized to receive either an
RCAVF (n  92) or prosthetic graft implant (n   90) (Fig
1). Patient characteristics of both groups are shown in
Table I. Preoperative assessment included a standard phys-
ical examination and blood pressure measurement on both
arms according to the Riva-Rocci method with a proximal
pressure cuff and auscultation of the brachial artery. All
patients underwent preoperative duplex ultrasonography of
the arteries and superficial veins of the upper extremity.
Duplex scanning was performed according to a standard
protocol by experienced vascular technicians. The angle of
the emitted Doppler ultrasound wave from the probe was
adjusted to 60 degrees to achieve the Doppler signal of the
strongest intensity. The anteroposterior internal diameter
of the vessel was measured using B-mode technique with a
proximal tourniquet to engorge the veins. Vessels were
diagnosed as obstructed when no Doppler signal could be
obtained. From the literature, we defined certain vessel
diameters as cutoff values for randomization. When the
radial artery had a diameter 1 mm with or without an
absent cephalic vein, patients were allocated to implanta-
tion of a prosthetic brachial-antecubital forearm loop ac-
cess. When the radial artery was 2 mm and the cephalic
vein was 1.6 mm, an RCAVF was created. Patients with a
radial artery between 1 and 2 mm and/or a cephalic vein
1.6 mm were randomized for the creation of either an
RCAVF or prosthetic brachial-antecubital forearm loop.
The number of complications and interventions were
registered and primary, assisted primary, and secondary
patencies were calculated by life table methods.
Surgical procedure. All procedures were performed
under local/regional or general anesthesia with the use of
antibiotic prophylaxis. RCAVFs were constructed by ex-
posing the radial artery and cephalic vein through a longi-tudinal or transverse incision 4-5 cm proximal of the radial
styloid process. After sufficient vein mobilization an end-
to-side vein-to-artery anastomosis was performed with a
running 7-0 polypropylene monofilament suture (Prolene;
Ethicon, Johnson & Johnson, Amersfoort, The Nether-
lands). The length of the arteriotomy was 10-15 mm and
internal vessel diameters were measured with coronary
probes. Thin-walled stretch PTFE grafts (Gore-Tex, WL
Gore & Associates, Flagstaff, Ariz) with a wall thickness of
0.5 mm and an internal diameter of 6 mm, were positioned
in a subcutaneous loop with the use of a tunneler device in
the forearm between the brachial artery and a suitable
elbow vein. Arterial and venous anastomoses were created
with running 7-0 polypropylene sutures. AVF patency was
confirmed perioperatively by palpation and Doppler exam-
ination. Coumarin (Sintrom [acenocoumarol]; Novartis
Pharma GmbH, Nürnberg, Germany) was given after sur-
gery to all patients in a dose that was sufficient for an
adequate anticoagulation (international normalized ratio
2.5) for a period of 3 months. Postoperative evaluation
was done by palpation and auscultation. Patients were
regularly seen by the nephrologist, and the decision to start
dialysis treatment was made based on the severity of dete-
rioration of renal function. The first cannulation of the
RCAVF was performed when the vessels had matured
adequately, usually after 4-6 weeks. When cannulation was
not possible due to nonmaturation, dialysis was started by
means of a central vein catheter.
Follow-up. Clinical follow-up was performed during
a 12-month period. Early and late complications and radio-
graphic and surgical interventions were registered. Compli-
cations were treated according to the standard clinical
practice of the hospital where the patient was being dia-
lyzed. Patency was defined as functional patency with ade-
quate dialysis. Clinical criteria were used for detection of
AVF thrombosis and nonmaturation. Inability to cannulate
the AVF or to obtain sufficient dialysis blood flow (250
mL/min) within 6 weeks after fistula creation were indica-
tors of a poorly functioning AVF. All patients with nonma-
turing RCAVFs underwent angiography, visualizing the
proximal arterial inflow by retrograde contrast filling initi-
ated through a proximal occluding cuff. Venous outflow
vessels were imaged by contrast injection after the release of
the proximal cuff.
End points. End points were defined as AVF failure,
death, successful kidney transplantation, or transfer to con-
tinuous ambulatory peritoneal dialysis (CAPD) treatment.
Statistical analysis. For statistical analysis, the statisti-
cal package of SPSS 11.0 for Windows (SPSS, Inc., Chi-
cago, Ill) was used. Before the start of the study, a power
calculation had been performed to determine the number
of patients needed per group to demonstrate an improve-
ment in 1-year primary patency rate of 18%. For a power of
80%, at   0.05, the resulting group size was 90 patients
per study group. The incidence rate was defined as the
number of complications or interventions per patient-year
(py), the cumulative follow-up time of all patients and
analyzed with the Mann-Whitney test. Patency rates were
on of
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with the log-rank test. Primary patency rate was defined as
the percentage of AVFs that functioned well without any
intervention after implantation. Assisted primary patency
rate was defined as the percentage of failing but still patent
AVFs undergoing elective intervention, and secondary pa-
tency was defined as the proportion of patent AVFs still in
use for hemodialysis after successful intervention for
thrombosis.11 Patients with a patent AVF who died, re-
ceived a kidney transplant, or were withdrawn from hemo-
dialysis alive were censored. Differences were considered
statistically significant when P  0.05.
RESULTS
Of the patients randomized for an RCAVF, one patient
was still waiting for an operation, one patient underwent a
successful kidney transplantation while waiting for an op-
eration, three patients died before undergoing the opera-
tion, and one patient was lost to follow-up. A total of 86
patients randomized for an RCAVF were subjected to
further analysis. Six patients exhibited insufficient wrist
vessels noticed during the operation and received PTFE
Fig 1. Algorithm for the creati
Table I. Patient characteristics in patients with RCAVF
and prosthetic AVF
RCAVF Prosthetic AVF
No. 86 84
Male 44 (51%) 45 (54%)
Mean age (y) 57.6 62.5
Diabetes 27 (31%) 26 (31%)
Hypertension 69 (80%) 56 (67%)
Ischemic cardiac disease 11 (13%) 17 (20%)
Peripheral arterial obstructive disease 13 (15%) 18 (21%)
Cerebrovascular disease 9 (10%) 12 (14%)
RCVAF, radial-cephalic direct wrist arteriovenous fistula; AVF, arterio-
venous fistula.graft AVFs. These six cases were considered primary fail-ures. Fifty-nine percent of the RCAVFs were functional for
dialysis treatment after 6 weeks, resulting in a primary
failure rate of 41% due to early thrombosis (n  8), failure
to mature (n  21), or insufficient vessels noticed during
operation (n  6). After 6 weeks, one patient developed
steal (1.2%) with the need for fistula ligation, one patient
was lost to follow-up, one patient stopped dialysis treat-
ment, and eight patients died in the first year after creation
of the RCAVF. Of the patients randomized for a prosthetic
AVF, two patients were still on the list for operation, and
four patients died before undergoing the operation. A total
of 84 patients randomized for prosthetic graft implant were
subject for further analysis. In one patient, it was not
possible to implant a prosthetic graft due to abnormal
vascular anatomy at the elbow; this patient received an
RCAVF. The mean brachial artery diameter in the pros-
thetic group was 3.8 mm (range, 2.0-6.0 mm) and the
mean cephalic vein diameter at the elbow was 3.1 mm
(range, 0.8-7.2 mm). In only one patient, thrombotic
occlusion occurred within the first 6 weeks after operation.
No attempt at revision was made, and this patient received
a new vascular access. Thus, 98% of prosthetic graft AVFs
were functional for dialysis treatment. One patient devel-
oped a steal syndrome (0.01/py), five patients were lost to
follow-up, one patient stopped cooperating with the study,
17 patients died of complications of their renal failure with
a patent graft, three patients underwent successful kidney
transplantation, two patients switched to peritoneal dialy-
sis, and in two patients, the graft was explanted because of
infection (0.02/py).
Patients with RCAVFs developed a total of 102 (1.19/
py) vs 122 (1.45/py; P  .739) complications in the
prosthetic AVFs (Table II). The incidence of thrombosis
was significantly higher in the prosthetic graft group
(0.54/py vs 0.19/py; P  .049). Also infection was seen
significantly more often in patients with prosthetic grafts
(0.13/py vs 0.03/py; P  .009). Pseudoaneurysm forma-
vascular access in new patients.tion was only seen in the prosthetic AVF group. A total of
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(0.94/py) in the prosthetic graft group were needed for
access salvage (P  .077) (Table III). Significantly more
surgical thrombectomies were done in the prosthetic graft
group (0.45/py vs 0.10/py; P  .008). However, percu-
taneous transluminal angioplasty (PTA) was almost equally
performed in both groups (0.26/py in the RCAVF group
vs 0.30/py in the prosthetic graft group; P  .437). In
addition, surgical revisions (0.10/py in the RCAVF group
vs 0.05/py in the prosthetic graft group; P  .086) were
executed for access salvage.
Of the 43 interventions in the RCAVF group, 13
interventions were performed in nine patients to improve
maturation. Anastomotic stenosis in two patients was suc-
cessfully treated by PTA. In two other patients, PTA failed,
and in these two subjects, a prosthetic graft was implanted.
One subject underwent repeated PTA for cephalic vein
stenosis, without success. Therefore, a surgical revision was
performed, also without success. Finally, after a last unsuc-
cessful PTA, the patient received a new AVF in the con-
tralateral arm. Another three patients underwent unsuc-
cessful surgical revisions, including basilic vein transpo-
sition, venous interposition, and ligation of tributary veins.
Last, one patient underwent two surgical interventions,
with ligation of tributary veins, followed by a new proximal
radiocephalic anastomosis. However, in these patients, sur-
gical revisions failed and prosthetic grafts were implanted.
At the end, two of nine patients with nonmatured RCAVFs
received successful interventions.
Primary and assisted primary 1-year patencies were 33%
 5.3% vs 44%  6.2% (P  .03; Fig 2) and 48%   5.5% vs
63%  5.9% (P  .035; Fig 3) for RCAVF and prosthetic
AVF, respectively. Secondary patencies were 52%  5.5%)
vs 79% ( 5.1%) (P  .0001; Fig 4) for RCAVF and
prosthetic AVF, respectively.
DISCUSSION
For the past decades, the autogenous RCAVF has been
Table II. Number of complications per patient-year in
RCAVF group and prosthetic AVF group
RCAVF Prosthetic AVF P
No. 86 84 —
Hematoma 0.20 0.13 NS
Seroma 0 0.02 NS
Infection 0.03 0.13 .009
Thrombosis 0.19 0.54 .049
Pseudoaneurysm 0 0.10 .006
Steal syndrome 0.01 0.01 NS
Stenosis 0.29 0.30 NS
Nonmaturation 0.24 — —
Inability to cannulate 0.14 0.05 NS
Bleeding 0.02 0.04 NS
Others 0.06 0.14 NS
Total no. of complications 1.19 1.45 NS
RCAVF, radial-cephalic direct wrist arteriovenous fistula; AVF, arterio-
venous fistula; NS, not significant.accepted as the vascular access of first choice. Therefore, itseems logical to obtain autogenous fistulas in all new dial-
ysis patients. However, data from a recent meta-analysis
show a high primary failure rate andmoderate patency rates
at 1 year of follow-up.12 Similar outcomes could be con-
firmed by the current study in which a high primary failure
rate of 41% and moderate 1-year patencies of 33% and 52%
(primary and secondary, respectively) were found in the
patients with RCAVFs. This is mainly due to early postop-
erative thrombosis and failure to mature. Nonfunctioning
vascular access results in delay of initiation of dialysis treat-
ment with additional morbidity. Access abandonment leads
to the need for temporary central vein catheter placement
with the risk of catheter thrombosis (24%-40%),13-15 infec-
tion and sepsis (2%-18%),14-16 and central vein obstruction
(30%).17 Usually, primary failure of RCAVFs depends on
the quality and size of the vessels used for the arteriovenous
anastomosis and the ability of vessel adaptation (remodel-
ing) induced by the increased blood flow volumes. An
adequate preoperative vessel assessment with noninvasive
Doppler ultrasonography can select well-sized arteries and
veins for RCAVF creation with subsequent improvement in
the outcome of the vascular access.8-10 Certain duplex-
derived parameters may predict the risk of failure or dys-
Fig 2. Primary patency rates. Patency rate is shown in percentages
and time in months. Number of patients is presented in the graph.
P values calculated with the log-rank test.
Table III. Number of interventions per patient-year in
RCAVF group and prosthetic AVF group
RCAVF Prosthetic AVF P
No. 86 84 —
PTA 0.26 0.30 NS
Surgical thrombectomy 0.10 0.45 .008
Surgical revision 0.10 0.05 NS
Other interventions 0.03 0.14 .028
Total no. of interventions 0.50 0.94 NS
RCAVF, radial-cephalic direct wrist arteriovenous fistula; AVF, arterio-
venous fistula; NS, not significant.maturation. The internal radial artery diameter has been
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or to plan strategies for vascular access. Wong et al18
observed primary failure of RCAVFs in patients with a
radial artery and/or cephalic vein diameter 1.6 mm.
Strategies for vascular access creation can be based on
preoperative duplex scanning. Patients with a radial artery
diameter of 2 mm and a cephalic vein diameter of 2.5
mm received RCAVFs, with, as result, a low primary failure
rate of 8%.9 However, there is still debate whether RCAVFs
should be performed in patients with very small and/or
diseased poor vessels. An “all autogenous” vascular access
policy, including creation of fistulas with small vessels,
probably results in high primary failure rates and the need
for multiple interventions. Until today, no studies are avail-
able that elucidate this subject and that was the reason for
performing the present study and investigating which
method for hemodialysis vascular access in patients with
Fig 3. Assisted primary patency rates. Patency rate is shown in
percentages and time in months. Number of patients is presented
in the graph. P values calculated with the log-rank test.
Fig 4. Secondary patency rates. Patency rate is shown in percent-
ages and time in months. Number of patients is presented in the
graph. P values calculated with the log-rank test.poor forearm vessels may be the best option. In this study,we found a dismal 1-year primary patency of 33% in the
RCAVF group compared to 44% in the prosthetic AVF
group. Also, a secondary patency of 52% at 1 year in the
RCAVF group was significantly lower compared to 79% in
the PTFE graft group. We conclude from these results that
patients with poor forearm vessels may possibly benefit
from implantation of a prosthetic graft, and this may a
better option than a primary autogenous radial-cephalic
direct wrist access. In addition, the primary selection of a
PTFE AVF in elderly patients may be worthwhile, given the
reduced life expectancy of these patients (50%mortality at 2
years)19 and the risk of long periods of indwelling central
vein catheters with their related morbidity, when attempts
to make nonmatured fistulas functioning fail.
One limitation of this study is the relatively short
follow-up period of 1 year, because it is conceivable that
there may be patency advantage for the RCAVF beyond 1
year. Another limitation is the fact that the duplex measure-
ments of the vessel diameters were performed only once.
There may be some variation in vessel diameter measured at
different times and different days. Also, there may be influ-
ence of regional anesthesia on vessel diameters due to a
vasodilatation mechanism.
One might argue for trying to create autogenous fistu-
las in patients with poor vessels, and indeed still 52% of
patients who received an RCAVF in this study did develop
functioning access with ultimately fewer interventions for
access salvage (0.94/py vs 0.50/py interventions). Also,
when an RCAVF does fail, it is still possible to implant a
forearm prosthetic AVF. The total number of complica-
tions in RCAVFs is similar to those of prosthetic AVFs
(1.19/py vs 1.45/py). The number of thrombotic occlu-
sions was significantly higher in grafts, whereas nonmatu-
ration and cannulation difficulties occurred in RCAVFs in
particular.
Of the 43 interventions in the RCAVF group, 13
interventions were performed in nine patients to improve
maturation. Interventional treatment by means of PTA and
surgical revision resulted in maturation in only two patients
(22%). The impact of reintervention on fistula maturation
and maintenance was recently reported by two studies.20,21
In these studies, not only concerning radial-cephalic but
also brachial-cephalic and basilic AVFs, a 10% improvement
was seen in accomplishing a functional AVF, achieved by
either PTA or surgical intervention. In the current study,
only PTA was successful in accomplishing a functional
access in a minority of patients. In the other patients with
nonmatured accesses, beyond the 6-week period, no fur-
ther improvement was observed and these accesses were
replaced by alternative fistulas. An aggressive approach to
evaluate and intervene in immature fistulas may improve
the maturation rate. Beathard et al22 reported on their
experience with 71 patients referred because of inadequate
maturation of their fistulas. Eight were not evaluated fur-
ther because they were believed to have an inadequate
arterial inflow. The remaining 63 patients underwent an-
gioplasty of a stenotic lesion in the draining vein, ligation of
one or more tributary veins, or a combination of both
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the fistulas matured adequately to be used for dialysis.
Turmel-Rodriques et al23 reported in their study that in-
terventional radiology can treat the majority of cases and
achieve a 97% success rate. However, they also found out
that early recurrence of stenoses can occur.
Early detection and correction of hemodynamically
significant stenosis in both autogenous and prosthetic
AVFs reduce the thrombosis rates. In addition, interven-
tion with PTA or surgical revision to correct stenosis re-
duces the rate of AVF thrombosis.24-28 This preemptive
correction of AVF at risk of thrombosis should have the
additional economic impact of reducing emergency admis-
sions due to access thrombosis, reducing the need for tem-
porary access catheters with their attendant complications and
preventing underdialysis with its associated morbidity and
mortality rates. All patients in our study were on anticoagu-
lants for 3 months. In Europe, anticoagulant treatment of a
prosthetic graft, in particular, is quite common.
In the current study, a low infection incidence of
0.03/py in the RCAVF group and 0.13/py in the pros-
thetic AVF group was seen. Early postoperative wound
infection after RCAVF and prosthetic AVF construction
poses a high risk of wound dehiscence and secondary
hemorrhage. These patients require treatment with intra-
venous antibiotics and drainage of pus collections. Late-
onset infections of prosthetic AVFs often occur at cannula-
tion sites and may resolve with simple antibiotic therapy,
eventually combined with segmental graft replacement
through a new subcutaneous route.29,30 In cases of severe
infection and risk of sepsis, graft explantation is required.
The incidence of steal syndrome, in which a sufficient
proportion of the arterial flow is shunted away from the
distal upper extremity, resulting in peripheral ischemia, is
usually low in distal AVFs. Only two patients (one with an
RCAVF and one with a prosthetic graft) in our study
developed steal syndrome, necessitating access ligation.
In summary, we performed a prospective, randomized
study comparing primary RCAVF and prosthetic (PTFE)
implantation in patients with poor vessels. Although there
were more interventions needed for access salvage in the
PTFE group, we conclude that patients with poor forearm
vessels may benefit from implantation of a prosthetic graft.
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The authors report a randomized, controlled trial comparing
autogenous radiocephalic and prosthetic forearm accesses in pa-
tients with compromised vessels for the autogenous choice. They
should be commended for their efforts and study design given the
limited evidence in the literature to justify the choice of the various
access configurations. Indeed, the paucity of level 1 evidence is
staggering given the overwhelming number of patients on hemo-
dialysis in the United States and abroad. The authors found that
the primary (33% vs 44%) and secondary (52% vs 79%) annual
patency rates were higher for the prosthetic accesses, although the
associated complication (1.19 patients per year) and intervention
(0.94 patients per year) rates were also greater. These results are
not particularly surprising given the study inclusion criteria for the
autogenous access (radial artery diameter between 1 and 2 mm
and/or cephalic vein 1.6 mm) and the mean diameters for the
brachial artery (3.8 mm) and the cephalic vein (3.1 mm) in the
prosthetic group.
It is not particularly clear how the results of the study should
affect our clinical practices. Extending the indications for the
autogenous radiocephalic access to patients with compromised
vessels affords another access option that does not preclude a
subsequent prosthetic forearm access. However, there is a signifi-lation, including the prolonged use of temporary catheters among
the patients already on hemodialysis and the associated economic/
psychologic effects. Indeed, the increased emphasis on autogenous
accesses in the United States has resulted in the unintended con-
sequence of increasing their primary failure rates (nonmaturation).
The more pivotal question that merits a randomized, con-
trolled trial is the choice between a prosthetic forearm loop or an
autogenous brachiobasilic access given the K/DOQI that recom-
mend the autogenous radiocephalic and brachiocephalic routes as
their first and second access choices, respectively. The results of the
current study can be used to reach the opposite conclusion and
seem to justify extending the indications for autogenous radioce-
phalic access to these compromised patients. Indeed, the patency
rates for the autogenous and prosthetic accesses seem to parallel
each other after the initial failures are excluded, and it is conceiv-
able that the longer-term patency rates (1 year) for the autoge-
nous accesses may be superior. Furthermore, the results under-
score the importance of pre–end-stage renal disease care and the
importance of early referral to an access surgeon before initiating
dialysis to allow adequate time to achieve an effective access. It is
imperative to realize that maintaining an effective hemodialysis
access is a difficult problem that usually requires multiple proce-
dures and interventions and lifelong planning.
